

2018 Hepatic Insufficiency Drug Development- Pipeline Analysis Report

<https://marketpublishers.com/r/2B0BFC8D074EN.html>

Date: May 2018

Pages: 0

Price: US\$ 999.00 (Single User License)

ID: 2B0BFC8D074EN

Abstracts

Hepatic Insufficiency is a rare disease that can either present slow or rapid worsening of liver functioning. Young population is the most affected age group. The disease presents high mortality rates. Hepatitis infection, medication issues, alcohol are the primary reasons of the disease.

Over 30 companies and universities are focusing on developing treatment options for Liver Failure (Hepatic Insufficiency).

To assist investigators and funding and regulatory organizations, VPA Research has come up with a comprehensive report on Liver Failure (Hepatic Insufficiency) pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.

Current status, developmental phase, participating companies and entities, recent developments, orphan drug/fast track/other designations, drug class are provided for each Liver Failure (Hepatic Insufficiency) pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.

In addition to complete details of each product, the report provides key trends in Liver Failure (Hepatic Insufficiency) pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.

Contents

1 TABLE OF CONTENTS

1.1 List of Figures

1.2 List of Tables

2 HEPATIC INSUFFICIENCY PIPELINE ANALYSIS

2.1 Disease and Pipeline Overview

2.2 Hepatic Insufficiency Pipeline Snapshot

2.3 Hepatic Insufficiency Pipeline by Phase

2.4 Hepatic Insufficiency Pipeline by Company

2.5 Hepatic Insufficiency Pipeline by Mechanism of Action

3 HEPATIC INSUFFICIENCY- COMPANY WISE PIPELINE ANALYSIS

BioLineRx

Cell2B

HepaRegeniX GmbH

Martin Pharmaceuticals

Mina Therapeutics

Novartis AG

PledPharma AB

Promethera Biosciences

Proterris Inc

Steminent Biotherapeutics Inc

Therapure Biopharma

Unicyte AG

Versantis AG

Vital Therapies Inc

Xenexus Pharmaceuticals

4 HEPATIC INSUFFICIENCY R&D PIPELINE SNAPSHOTS

Drug wise Pipeline Details

Therapeutic Candidate Name

Originator

Co-Developer/License Partner

Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details

5 RECENT DEVELOPMENTS IN HEPATIC INSUFFICIENCY PIPELINE

6 APPENDIX

6.1 About VPA Research
6.2 Sources and Research Methodology

List Of Figures

LIST OF FIGURES

Figure 1: Hepatic Insufficiency Pipeline by Phase, H1- 2018

Figure 2: Hepatic Insufficiency Pipeline by Companies, H1- 2018

Figure 3: Company Wise Pipeline Drug Phases, H1- 2018

Figure 4: Hepatic Insufficiency Pipeline by Mechanism of Action, H1- 2018

Figure 5: Mechanism Wise Pipeline Drug Phases, H1- 2018

List Of Tables

LIST OF TABLES

- Table 1: Hepatic Insufficiency Pipeline by Phase, H1- 2018
- Table 2: Hepatic Insufficiency Pipeline by Companies, H1- 2018
- Table 3: Hepatic Insufficiency Pipeline by Mechanism of Action, H1- 2018
- Table 4: BioLineRx Hepatic Insufficiency pipeline, May 2018
- Table 5: Cell2B Hepatic Insufficiency pipeline, May 2018
- Table 6: HepaRegeniX GmbH Hepatic Insufficiency pipeline, May 2018
- Table 7: Martin Pharmaceuticals Hepatic Insufficiency pipeline, May 2018
- Table 8: Mina Therapeutics Hepatic Insufficiency pipeline, May 2018
- Table 9: Novartis AG Hepatic Insufficiency pipeline, May 2018
- Table 10: PledPharma AB Hepatic Insufficiency pipeline, May 2018
- Table 11: Promethera Biosciences Hepatic Insufficiency pipeline, May 2018
- Table 12: Proterris Inc Hepatic Insufficiency pipeline, May 2018
- Table 13: Steminent Biotherapeutics Inc Hepatic Insufficiency pipeline, May 2018
- Table 14: Therapure Biopharma Hepatic Insufficiency pipeline, May 2018
- Table 15: Unicyte AG Hepatic Insufficiency pipeline, May 2018
- Table 16: Versantis AG Hepatic Insufficiency pipeline, May 2018
- Table 17: Vital Therapies Inc Hepatic Insufficiency pipeline, May 2018
- Table 18: Xenexus Pharmaceuticals Hepatic Insufficiency pipeline, May 2018

I would like to order

Product name: 2018 Hepatic Insufficiency Drug Development- Pipeline Analysis Report

Product link: <https://marketpublishers.com/r/2B0BFC8D074EN.html>

Price: US\$ 999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/2B0BFC8D074EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970